These results suggest that IL-6 inhibitors, Tocilizumab and CIGB-258, produce similar improvements in the plasma lipid profiles, while TNF-α inhibitors (Infliximab and Etanercept) did not improve the lipid profile and hepatic inflammation caused by CML treatment in zebrafish. Here, IL6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.